Pancreatic parenchymal of N-butyl-2-cyanoacrylate
Phase 2Small molecule
Pancreatic parenchymal of N-butyl-2-cyanoacrylate is one of 6 small molecule programs targeting Pancreatic. It is currently in Phase 2.
2
Indications
2
Total Trials
2
Active Trials
5
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
6 competitors in Pancreatic
#DrugCompanyPhaseTrials
1Nolvadex
AstraZenecaPhase 1
Adstiladrin
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Phase 1
Pancreatic parenchymal of N-butyl-2-cyanoacrylate
MMinia University
Phase 2
Synthetic Human Secretin
MMayo Clinic
Preclinical
Proton Pump Inhibitors
SSamsung Medical Center
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- MMinia University